ABL receives NIAID contract
Under the $102m contract, titled as "Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases", ABL will provide services from early feasibility studies through
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The acquisition follows the previously announced asset purchase agreement. WBI-1001 is a non-steroidal, topical anti-inflammatory new chemical entity (NCE) agent, which has demonstrated efficacy and safety in Ph1